Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Centessa Pharmaceuticals (CNTA) Amortization of Deferred Charges (2025 - 2026)

Centessa Pharmaceuticals has reported Amortization of Deferred Charges over the past 1 years, most recently at $279000.0 for Q4 2025.

Quarterly Amortization of Deferred Charges changed N/A to $279000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
Amortization of Deferred Charges was $279000.0 for Q4 2025 at Centessa Pharmaceuticals, up from $271000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $312000.0 in Q1 2025 and troughed at $271000.0 in Q3 2025.